Reviva Pharmaceuticals Holdings (RVPH) EBT (2018 - 2026)
Reviva Pharmaceuticals Holdings (RVPH) posted EBT of -$3.2 million for Q1 2026, up 7.54% sequentially from -$3.5 million in Q4 2025, and up 50.33% YoY from -$2.1 million in Q1 2025.
Reviva Pharmaceuticals Holdings (RVPH) EBT (2018 - 2026) Analysis & Trends
Reviva Pharmaceuticals Holdings has reported EBT for 9 years, with the latest figure at -$3.2 million in Q1 2026.
- Quarterly EBT rose 50.33% year-over-year to -$3.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$16.7 million (down 1862.9% YoY) and the FY2025 annual result came in at -$19.9 million, down 38737.66% from the prior year.
- EBT improved to -$3.2 million in Q1 2026 per RVPH's latest filing, from -$3.5 million in the prior quarter.
- Over five years, EBT peaked at $23.6 million in Q4 2024 and troughed at -$12.0 million in Q4 2022.
- A 5-year average of -$5.3 million and a median of -$6.8 million in 2023 frame the typical range for EBT.
- The sharpest annual moves came in 2022 and 2024: EBT sank 676.11% in 2022, then surged 350.52% in 2024.
- Over 5 years, EBT stood at -$12.0 million in 2022, then advanced by 21.73% to -$9.4 million in 2023, then jumped by 350.52% to $23.6 million in 2024, then sank by 114.64% to -$3.5 million in 2025, then increased by 7.54% to -$3.2 million in 2026.
- According to Business Quant data, EBT over the past three periods registered -$3.2 million, -$3.5 million, and -$4.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | Reviva Pharmaceuticals Holdings | 6.47 Mn | 6.47 Mn | - | -2.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.45 Mn |
| Mar 31, 2026 | -3.19 Mn |
| Dec 31, 2025 | -3.45 Mn |
| Sep 30, 2025 | -4.01 Mn |
| Jun 30, 2025 | -6.05 Mn |
| Mar 31, 2025 | -6.43 Mn |
| Dec 31, 2024 | 23.59 Mn |
| Sep 30, 2024 | -8.37 Mn |
| Jun 30, 2024 | -7.85 Mn |
| Mar 31, 2024 | -7.43 Mn |
| Dec 31, 2023 | -9.42 Mn |
| Sep 30, 2023 | -11.33 Mn |
| Jun 30, 2023 | -11.70 Mn |
| Mar 31, 2023 | -6.85 Mn |
| Dec 31, 2022 | -12.03 Mn |
| Sep 30, 2022 | -3.51 Mn |
| Jun 30, 2022 | -5.33 Mn |
| Mar 31, 2022 | -7.36 Mn |
| Dec 13, 2021 | -3.68 Mn |
| Sep 30, 2021 | -2.28 Mn |